In this study, we found that the genetic SCN5A T220I variant acts like a lifelong sodium channel blocker, mostly providing protection from diverse cardiac arrhythmias, while also increasing risk of bradyarrhythmias, similar to sodium channel blocker side effects. The gene discussed is SCN5A; the disease is chronic obstructive pulmonary disease.